Cumberland Pharms patents expiration
1. Acetadote patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399445 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(1 year, 3 months from now) | |
| US8653061 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(1 year, 3 months from now) | |
| US8148356 | CUMBERLAND PHARMS | Acetylcysteine composition and uses therefor |
May, 2026
(2 years from now) | |
| US9327028 | CUMBERLAND PHARMS | Acetylcysteine compositions and methods of use thereof |
Jul, 2031
(7 years from now) | |
| US8722738 | CUMBERLAND PHARMS | Acetycysteine compositions and methods of use thereof |
Apr, 2032
(7 years from now) | |
| US8952065 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Feb, 2035
(10 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy
Dosage: INJECTABLE;INTRAVENOUS
ACETADOTE family patents
2. Caldolor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6727286 | CUMBERLAND PHARMS | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
Nov, 2021
(2 years ago) | |
| US8871810 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9114068 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US8735452 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9295639 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9138404 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9649284 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9012508 | CUMBERLAND PHARMS | Administration of intravenous ibuprofen |
Sep, 2030
(6 years from now) | |
| US9072661 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
| US9072710 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
| US11806400 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Nov 19, 2024 |
| New Patient Population(NPP) | May 11, 2026 |
| New Product(NP) | Jun 11, 2012 |
| New Dosing Schedule(D-152) | Nov 20, 2018 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Method...
Dosage: SOLUTION;INTRAVENOUS
CALDOLOR family patents